Angel sign new contract with ReNeuron
Angel Biotechnology Holdings Plc

5 November 2012

Angel Biotechnology Holdings plc

("Angel" or "the Group")

Manufacturing Contract for ReNeuron Drug Substance

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce the signing of a new contract with ReNeuron Group plc.  This contract relates to the expansion of CTX cells, the production of a GMP Drug Substance batch and associated testing.  The contract is scheduled for completion in the current financial year.

Mr Nicholas Smith, Non-Executive Chairman of Angel said: "Angel continues to build on its track record of providing its expertise and services to ReNeuron Group plc.  The new contract will demonstrate Angel's ongoing ability to respond to the needs of its clients to provide high quality, reliable and value-for-money services."

Mr Michael Hunt, CEO of ReNeuron Group plc said: "Angel remains a key player in the supply chain of our clinical material. This contract will ensure the provision of further Drug Substance material required to service our on-going therapeutic programmes. "

For further information:

Angel Biotechnology Holdings plc                                                                                                                       

Nicholas Smith, Non-Executive Chairman                                                                 +44 (0) 131 445 6077

www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean                                                                                    +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce, Deepak Reddy                                                                                           +44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Philip Ranger / Caolan Mahon                                                                           +44 (0) 20 7536 2028 / 2029

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly.  In addition, Angelprovides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements.Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA) and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from pioneering biotechnology companies such as ReNeuron Group plc to established pharmaceutical companies such as Russian-based Materia Medica Holdings. 

Angel has three facilities: Pentlands Science Park near Edinburgh, a site in Cramlington, near Newcastle-upon-Tyne and Angel Biomedical Ltd facility in Glasgow.

More information is available atwww.angelbio.com .

- Ends -


This information is provided by RNS
The company news service from the London Stock Exchange
END MSCBUBDBDBGBGDD
distributed by